Overview
Double Jeopardy: COVID-19, the Evil Character for ILD Patients
COVID-19 and Pulmonary Fibrosis Vlog
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Patients with progressive CF-ILD are an extremely high-risk group for mortality with COVID-19 infection. Thus, proper knowledge of concomitant COVID-19 infection and ILD management is imperative. Upon completion of this activity, clinicians will be better able to assess for concomitant COVID-19 infection and ILD, as well as enhance their ability to optimize care in patients who present with both of these diseases.
This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.
What do you do when your patients with ILD contract COVID-19? This 15-minute CME-certified vlog, featuring leading pulmonology experts, Paul Noble, MD and Tanzira Zaman, MD, will break down the key assessment and management tactics.
Learn more about the:
• Presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
• Recommended strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
Learn more about the:
• Presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
• Recommended strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
Upon completion of this activity, participants will be able to:
• Indicate the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
• Implement recommended strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
• Indicate the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
• Implement recommended strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Paul Noble, MD
Professor and Chair, Department of Medicine
Director, Women’s Guild Lung Institute
Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine
Physician-in-Chief
Cedars-Sinai Medical Center
Los Angeles, CA
Professor and Chair, Department of Medicine
Director, Women’s Guild Lung Institute
Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine
Physician-in-Chief
Cedars-Sinai Medical Center
Los Angeles, CA
Tanzira Zaman, MD
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Paul Noble, MD
Consultant (Occasional): Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone, and other treatments not yet approved to treat COVID-19.
*As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.
The following financial relationships have been provided:
Paul Noble, MD
Consultant (Occasional): Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone, and other treatments not yet approved to treat COVID-19.
*As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
